PharmaCyte Biotech Inc
For the period ended Jul 31, 2024. Filed Sep 17, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jul 31, 2024 · Filed Sep 17, 2024
PMCB$0.41+13.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit No. | Description | Location |
| 3.1 | Certificate of Designations of Preferences and Rights of Series B Convertible Preferred Stock | Incorporated by reference from Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 11, 2023. |
| 3.2 | Certificate of Change to Articles of Incorporation of the Company, dated September 6, 2023 | Incorporated by reference from Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on September 7, 2023 |
| 3.3 | Amendment No. Six to Bylaws of PharmaCyte Biotech, Inc. | Incorporated by reference from Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on July 19, 2023. |
| 10.1 | Securities Purchase Agreement, dated May 20, 2024, by and among PharmaCyte Biotech, Inc. and MyMD Pharmaceuticals, Inc. | Incorporated by reference from Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Commission on May 23, 2024. |
| 10.2 | Form of Certificate of Designations, dated May 20, 2024, by and among PharmaCyte Biotech, Inc. and MyMD Pharmaceuticals, Inc. | Incorporated by reference from Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Commission on May 23, 2024. |
| 10.3 | Form of Long-Term Warrants, dated May 20, 2024, by and among PharmaCyte Biotech, Inc. and MyMD Pharmaceuticals, Inc. | Incorporated by reference from Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the Commission on May 23, 2024. |
| 10.4 | Form of Short-Term Warrants, dated May 20, 2024, by and among PharmaCyte Biotech, Inc. and MyMD Pharmaceuticals, Inc. | Incorporated by reference from Exhibit 10.4 to the Company’s Current Report on Form 8-K filed with the Commission on May 23, 2024. |
| 10.5 | Registration Rights Agreement, dated May 20, 2024, by and among PharmaCyte Biotech, Inc. and MyMD Pharmaceuticals, Inc. | Incorporated by reference from Exhibit 10.5 to the Company’s Current Report on Form 8-K filed with the Commission on May 23, 2024. |
| 31.1 | Principal Executive Officer Certification required by Rules 13a-14 and 15d-14 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | Filed herewith |
| 31.2 | Principal Financial Officer Certification required by Rules 13a-14 and 15d-14 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | Filed herewith |
| 32.1 | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002 | Furnished herewith |
| 32.2 | Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002 | Furnished herewith |
| 101.INS | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and included in exhibit 101). |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.